公开(公告)号：US20210161954A1

公开(公告)日：2021-06-03

申请号：US16498899

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Philippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/02 ,  A61K31/365 ,  C07K14/705 ,  C07K14/725

Abstract: The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US10752670B2

公开(公告)日：2020-08-25

申请号：US15575707

申请日：2016-05-20

Applicant: Cellectis

Inventor： Julianne Smith ,  Cècile Schiffer-Mannioui

IPC: C07K14/725 ,  A61K39/00 ,  C07K14/705 ,  C07K14/735 ,  C07K16/30 ,  C12N5/0783 ,  A61K38/00

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.

公开(公告)号：US10426795B2

公开(公告)日：2019-10-01

申请号：US14403937

申请日：2013-05-13

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: C12N5/10 ,  A61K38/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10342829B2

公开(公告)日：2019-07-09

申请号：US14018021

申请日：2013-09-04

Applicant: CELLECTIS

Inventor： Julianne Smith ,  Andrew Scharenberg ,  Cecile Mannioui ,  Justin Eyquem

IPC: A61K35/17 ,  A61K38/00 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs. Such CARs, which aim to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties, comprise separate extracellular ligand binding and signaling domains in different transmembrane polypeptides. 91The signaling domains are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20150315557A1

公开(公告)日：2015-11-05

申请号：US14744668

申请日：2015-06-19

Applicant: CELLECTIS

Inventor： Andre Choulika ,  Frederic Cedrone ,  Julianne Smith

IPC: C12N9/22

CPC classification number: C12N9/22 ,  A61K38/00 ,  C12N2710/16622 ,  C12N2730/10122 ,  Y02A50/467

Abstract: An I-CreI variant, wherein at least one of the two I-Cre1 monomers has at least two substitutions, one in each of the two functional subdomains of the LAGLIDADG core domain situated from positions 26 to 40 and 44 to 77 of I-CreI, said variant being able to cleave a DNA target sequence from the genome of a non-integrating virus, in particular herpes simplex virus (HSV) or Hepatitis B virus (HBV) for use in genome engineering and for in vivo and ex vivo (gene cell therapy) genome therapy as well as the treatment of a virus infection.

Abstract translation: I-CreI变体，其中两个I-Cre1单体中的至少一个具有至少两个取代，位于位于I-CreI的位置26至40和44至77的LAGLIDADG核心结构域的两个功能亚结构域的每一个中的一个 所述变体能够从非整合型病毒，特别是单纯疱疹病毒（HSV）或乙型肝炎病毒（HBV）的基因组中切割DNA靶序列用于基因组工程和体内和离体（基因 细胞治疗）基因组治疗以及病毒感染的治疗。

公开(公告)号：US11944643B2

公开(公告)日：2024-04-02

申请号：US16498899

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Julianne Smith ,  Philippe Duchateau ,  Murielle Derrien

IPC: A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US11891614B2

公开(公告)日：2024-02-06

申请号：US16876079

申请日：2020-05-17

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: C12N15/87 ,  C07H21/04 ,  C12N15/85 ,  A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A01K67/00 ,  A61K39/00 ,  A61K38/00

CPC classification number: C12N15/85 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C12N5/0636 ,  A61K38/00 ,  A61K39/00 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US11304975B2

公开(公告)日：2022-04-19

申请号：US14889686

申请日：2014-05-13

Applicant: CELLECTIS

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cécile Schiffer-Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: A61K48/00 ,  C07H21/04 ,  A61K35/17 ,  C07K14/705 ,  C12N15/85 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  A01K67/00 ,  A61K39/00 ,  A61K38/00

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US10378026B2

公开(公告)日：2019-08-13

申请号：US14915434

申请日：2014-09-02

Applicant: CELLECTIS

Inventor： Andrew Scharenberg ,  Julianne Smith ,  Roman Galetto

IPC: C12N15/86 ,  C12N7/00

Abstract: The present invention relates to viral transformation method, particularly foamy virus-mediated transformation method. The present invention relates to the transfer of transgene into cells by the safe and efficient transfer of RNA encoding foamy components. The present invention has therefore therapeutic interest, especially in the field of gene therapy.

公开(公告)号：US10286007B2

公开(公告)日：2019-05-14

申请号：US15659792

申请日：2017-07-26

Applicant: Cellectis

Inventor： Roman Galetto ,  Agnes Gouble ,  Stephanie Grosse ,  Cecile Mannioui ,  Laurent Poirot ,  Andrew Scharenberg ,  Julianne Smith

IPC: C12N15/63 ,  C12N5/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28 ,  C07K14/705 ,  A61K38/00

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.